METHODS OF IDENTIFYING A SUBJECT WITH A TUMOR SUITABLE FOR A CHECKPOINT INHIBITOR THERAPY

The disclosure provides a method of treating a tumor in a human subject in need thereof, comprising administering an effective amount of a checkpoint inhibitor to the subject, wherein the subject meets at least two of the following conditions: the subject is identified as having a parenchymal inflam...

Full description

Saved in:
Bibliographic Details
Main Authors SZUSTAKOWSKI, Joseph Daniel, ADYA, Neeraj, VITAZKA, Patrik, FELTQUATE, David, NADLER, Steven Gary, SZABO, Peter M, CAR, Bruce David
Format Patent
LanguageEnglish
French
Published 14.05.2021
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The disclosure provides a method of treating a tumor in a human subject in need thereof, comprising administering an effective amount of a checkpoint inhibitor to the subject, wherein the subject meets at least two of the following conditions: the subject is identified as having a parenchymal inflammatory phenotype, wherein the parenchymal inflammatory phenotype is determined by measuring the expression of a panel of genes comprising at least 5 genes in a sample obtained from the subject; at least 1% of tumor cells in the tumor are positive for PD-L1 expression; and the subject exhibits a tumor mutation burden (TMB) status of at least about 10 mutations per megabase of genes examined. L'invention concerne une méthode de traitement d'une tumeur chez un sujet humain en ayant besoin, comprenant l'administration d'une quantité efficace d'un inhibiteur de point de contrôle au sujet, le sujet répondant à au moins deux des conditions suivantes : le sujet est identifié comme ayant un phénotype inflammatoire parenchymateux, le phénotype inflammatoire parenchymateux étant déterminé par mesure de l'expression d'un panel de gènes comprenant au moins 5 gènes dans un échantillon obtenu à partir du sujet ; au moins 1 % des cellules tumorales dans la tumeur sont positives pour l'expression de PD-L1 ; et le sujet présente une état de charge mutationnelle tumorale (TMB) d'au moins environ 10 mutations par mégabase de gènes examinés.
Bibliography:Application Number: WO2020US59174